drug development
Cancer therapy’s new ‘gold rush’
Adobe
Immune checkpoint inhibitors have been the MVP of cancer drugs in recent years. Merck’s Keytruda, for example, has been used against dozens of different cancers in millions of patients, making it the top-selling drug in the world. But experts say there’s a new player in town that could eventually challenge the dominance of these first generation treatments.
Drugs like Keytruda help the immune system to recognize and destroy cancer more aggressively. But a certain type of bispecific antibody — engineered to grab two different antigens at the same time — seems to have hit upon a crucial combination of cancer targets, PD-1 and VEGF. The exact biology isn’t clear yet, but scientists say the approach is promising.
Read more from STAT’s Angus Chen, who lays out the science behind this new approach.
addiction
Women with opioid use disorder aren’t getting as much birth control
Women being treated for opioid use disorder are less likely to be prescribed birth control than those in the general population, according to a study published yesterday in JAMA Internal Medicine. Researchers analyzed commercial insurance claims data from cisgender women ages 18 to 44 between 2016 and 2021.
While contraceptive prescriptions increased among women in the U.S. generally over the time period, from about 17% to 27%, the prescriptions decreased among those prescribed medications for opioid use disorder, from just over 12% in 2016 to 11.6% in 2021. It’s a sign that people struggling with addiction are not getting integrated, patient-centered birth control counseling as recommended by professional organizations, the authors write.